When disease is bad, Stage 4, or 5, leading toward

Quote:

---

When disease is bad, Stage 4, or 5, leading towards Cirrhosis, there will be many many more CCR5 on the hepatocytes and Kupfer cells, stellate cells.

When disease is light, Stage 1-3, no fibrosis, there will be minimal CCR5.

That is likely why 350 outperformed 700mg. The inflammed CCR5 took up all the leronlimab at low dose, while the uninflammed early stage disease had no CCR5 to receive the flood of leronlimab.

---

Even in stage 1 there is inflammation and higher than normal CCR5 expression. The disease progression is a cycle of inflammation, damage that increases inflammation and even more damage. At stage 1 and 2 with less CCR5 expression 350mg may be enough to provide coverage but 700mg would certainly provide the same occupancy so the results would be the same. So that is not a reason that 350mg would be better than 700mg. At higher stages of disease progression 700mg would have the advantage.